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Abstract
Background: The development of a successful new tuberculosis (TB) vaccine would circumvent many limitations
of current diagnostic and treatment practices. However, vaccine development is complex and costly. We aimed to
assess the potential cost effectiveness of novel vaccines for TB control in a sub-Saharan African country - Zambia -
relative to the existing strategy of directly observed treatment, short course (DOTS) and current level of bacille
Calmette-Guérin (BCG) vaccination coverage.
Methods: We conducted a decision analysis model-based simulation from the societal perspective, with a 3%
discount rate and all costs expressed in 2007 US dollars. Health outcomes and costs were projected over a 30-year
period, for persons born in Zambia (population 11,478,000 in 2005) in year 1. Initial development costs for single
vaccination and prime-boost strategies were prorated to the Zambian share (0.398%) of global BCG vaccine
coverage for newborns. Main outcome measures were TB-related morbidity, mortality, and costs over a range of
potential scenarios for vaccine efficacy.
Results: Relative to the status quo strategy, a BCG replacement vaccine administered at birth, with 70% efficacy in
preventing rapid progression to TB disease after initial infection, is estimated to avert 932 TB cases and 422 TB-
related deaths (prevention of 199 cases/100,000 vaccinated, and 90 deaths/100,000 vaccinated). This would result in
estimated net savings of $3.6 million over 30 years for 468,073 Zambians born in year 1 of the simulation. The
addition of a booster at age 10 results in estimated savings of $5.6 million compared to the status quo, averting
1,863 TB cases and 1,011 TB-related deaths (prevention of 398 cases/100,000 vaccinated, and of 216 deaths/100,000
vaccinated). With vaccination at birth alone, net savings would be realized within 1 year, whereas the prime-boost
strategy would require an additional 5 years to realize savings, reflecting a greater initial development cost.
Conclusions: Investment in an improved TB vaccine is predicted to result in considerable cost savings, as well as a
reduction in TB morbidity and TB-related mortality, when added to existing control strategies. For a vaccine with
waning efficacy, a prime-boost strategy is more cost-effective in the long term.
Background
N e a r l yat h i r do ft h ew o r l d ’s population harbors the
Mycobacterium tuberculosis bacillus, and about 1.7 mil-
lion people die of tuberculosis (TB) each year [1]. Since
the early 1990s, inconsistent treatment and the conse-
quent emergence of drug resistance, and widespread
HIV infection have contributed to the global epidemic.
Other major challenges include limited diagnostic tools,
and suboptimal provider/patient adherence with recom-
mended diagnostic and treatment interventions [2]. The
World Health Organization’s recommended strategy of
directly observed treatment, short course (DOTS) has
reduced incidence in most world regions; however, TB
control in sub-Saharan Africa and in the former Soviet
Union continues to be a particular concern [3,4]. In
response to these challenges, the World Health Organi-
zation (WHO) has broadened its approach to TB con-
trol, for example by considering HIV-TB co-infection,
smear-negative TB and treatment for latent infection
[5]. In addition, there is intensive research into novel
diagnostic, therapeutic, and preventive interventions.
The development of an effective TB vaccine holds great
appeal; by preventing TB infection and/or disease, it
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treatment strategies.
The only currently licensed TB vaccine, bacille Calm-
ette-Guérin (BCG), has proven at least modestly effica-
cious in preventing tuberculous meningitis and
disseminated disease in young children, although esti-
mates of protection vary [6,7]. It has very limited effi-
cacy in preventing adult pulmonary disease, the form of
disease that is contagious, and hence fuels the continu-
ing epidemic. Based on current development timelines,
next-generation TB vaccines may become available in
the next 5-7 years [8,9]. Because a suboptimal vaccine is
already in widespread use, an improved vaccine is likely
to attain the same or even better population coverage.
However, costs for development, testing, and implemen-
tation may be substantial. Given the limited resources
available for TB control, it is relevant to consider likely
costs and public health benefits of a novel vaccine,
based on currently available information. If vaccine
development is likely to prove very expensive, with pub-
lic health benefits accruing only in the distant future,
then other interventions may be accorded higher
priority.
Using a simulation model, we aimed to predict health
outcomes and costs with different scenarios for the
introduction of a novel TB vaccine in a sub-Saharan
African country. We were particularly interested in the
impact of varying scenarios for vaccine efficacy, and for
the mechanism and timing of vaccine effect. As a case
study, we estimated TB-related morbidity, mortality, and
costs of a novel TB vaccine introduced in Zambia, a
country with high HIV prevalence (9.4%) and very high
annual TB incidence (247 smear positive cases/100,000)
[1,10]. We projected changes in TB morbidity, mortality,
and cost when an improved vaccine replaces the current
BCG vaccination program, and supplements the current
DOTS program, over a range of scenarios for vaccine
efficacy.
Methods
General description of the model
We developed a decision analysis model, incorporating
multiple Markov processes, using TreeAge Pro Suite
2007 (TreeAge Software, Williamstown, MA). The
model estimated the probability of developing active TB
disease, TB mortality, and associated costs over a period
of 30 years for the existing TB control strategy (BCG
for newborns, plus DOTS based on smear diagnosis and
standard drug regimens), and for two alternative country
wide vaccination strategies. We simulated a hypothetical
fixed cohort of newborns who joined the existing popu-
lation of Zambia. The characteristics of the Zambian
population used for this simulation are summarized in
Table 1. The analysis was conducted from a societal
perspective, including both direct and indirect costs. All
future expenditures and outcomes were discounted at a
rate of 3% annually [11].
For the purpose of the primary analysis, current epide-
miologic and tuberculosis control parameters (Table 1)
were assumed to remain constant over the simulation
p e r i o d :a n n u a lr i s ko fT Bi n f e c t i o n ,D O T Sc o v e r a g e ,
case detection rate, treatment outcomes, smear-positive
incidence, HIV seroprevalence, and prevalence of initial
TB drug resistance. The status quo included the protec-
tive effects of existing BCG vaccination, at the current
level of vaccine coverage and with a presumed 50%
reduction in the risk of primary progression to pulmon-
ary disease, tuberculous meningitis or disseminated dis-
ease during early childhood [12,13]. The reduction in
risk conferred by existing BCG vaccination is assumed
to apply for a total duration of 10 years, but its protec-
tive effect is assumed to wane linearly to zero over this
period of time.
In primary analysis, the vaccination strategies that we
compared with the existing TB control program were,
1) vaccination with a novel TB vaccine at birth, and 2)
vaccination with a novel vaccine at birth plus a booster
dose at age 10. Both comparison strategies were
assumed to cover the same proportion of the target
population as the current BCG program. The protective
effect of all vaccine doses was assumed to be immediate,
and would then wane linearly to zero over a period of
10 years. In the primary analysis, the replacement TB
vaccine for neonates was assumed to have an initial effi-
cacy of 70% for preventing rapid progression to TB dis-
ease. Hence the replacement vaccine would work
similarly to BCG, but with greater efficacy. As a result,
the incidence of contagious smear-positive pulmonary
disease will remain largely constant during the first
years after introduction of the novel vaccine. This is
because young children develop primary, disseminated
and/or meningeal forms of the disease which are rarely
contagious.
The booster dose administered at the age of 10 was
also assumed to be 70% efficacious, and to work by pre-
venting rapid progression to active disease. Hence it
would only be of benefit to persons who had not yet
acquired latent TB infection by age 10.
Other potential mechanisms for vaccine action could
be to reduce: 1) acquisition of initial infection following
exposure to Mycobacterium tuberculosis; or 2) late reac-
tivation of longstanding latent TB infection. These alter-
nate mechanisms of vaccine action, and their impact on
health outcomes and costs, were considered in sensitiv-
ity analyses. For this reason, the time frame of all ana-
lyses was 30 years, so that potential benefits related to
protection against acquiring TB infection and to preven-
tion of late reactivation could be tracked into early
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compared outcomes at 5, 10, and 20 years.
Preliminary data suggest some novel TB vaccines cur-
rently under development will be safer than BCG for
administration to HIV-positive individuals [8,9]. The
model assumed all vaccines to have similar protective
efficacy in individuals with early HIV infection to that in
seronegative persons. We assumed that the vaccine had
no effect on the development of active TB in persons
with clinical AIDS, based on severe impairment of
cell-mediated immunity. To the extent that this could
underestimate vaccine benefit, this was a conservative
assumption.
Model health states, transitions, and calculations
In the model, TB-related health states, along with key
pathogenetic assumptions corresponding to Markov
state transition probabilities (e.g. risk of acquiring
tuberculosis infection, subsequent risk of active TB)
were as previously described [14,15], modified and
extended to include vaccination (Table 2).
Model cohort members were classified into five broad
TB-related health states: 1) uninfected; 2) latent tuber-
culosis infection (LTBI); 3) active tuberculosis; 4) suc-
cessfully treated, or spontaneously resolved active TB;
and 5) chronic TB (MDR-TB). Latent TB, active TB,
and spontaneously resolved active TB were further sub-
divided into three categories based on drug sensitivity:
drug sensitive, single-drug resistant, or multi-drug resis-
tant. The annual risk of infection was calculated from
the estimated incidence of smear-positive cases using
the Styblo formula [16]. We estimated that a new TB
infection would progress to active disease in 5% of HIV-
negative individuals within 2 years of acquiring the
infection [17], and long-standing LTBI would re-activate
at an annual rate of 0.1% thereafter in HIV-negative
Table 1 Epidemiologic and Program Data for Zambia
Variable Value Source
Population (2005) 11,478,000 [56]
Live births/1,000 population (2007) 40.78 [57]
Live births per year 468,073 Calculated from [56,57]
Percent of global BCG vaccine coverage 0.398% [34]
Percent of target population vaccinated with BCG 92% [34]
Gross National Income per capita (US$) 2005 $500 [58]
Life expectancy at birth (years) 38.4 [58]
All cause mortality Age specific [59]
New estimated TB smear-positive incidence per 100,000 (2005) 247 [1]
Annual risk of TB infection (ARI) 4.94% Calculated from [1,16]
Probability of being diagnosed and treated for LTBI 1% [20]*
Completion of LTBI treatment 67% [21]
HIV prevalence (2006) 9.4% [10]
HIV incidence per annum 0.96% Calculated from [22]
DOTS coverage (2005) 100% [1]
DOTS case detection rate (2005) 52% [1]
Initial drug resistance
Single drug resistance 8.5% [60]
Multi drug resistance† 1.8% [61]
DOTS new case treatment outcomes (2005) [1]
Cure/complete 83%
Default/transfer/not evaluated 8%
Die 8%
Fail 1%
DOTS re-treatment outcomes (2005) [1]
Cure/complete 78%
Default/transfer/not evaluated 7%
Die 13%
Fail 2%
*This assumes only dually infected individuals (HIV and TB) whose HIV infection is detected and are tuberculin tested will be treated (based on a Haitian study).
†Defined as resistance to isoniazid and rifampin, with or without other drug resistance.
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and middle- income countries have focused largely on
active cases, with limited treatment of latent infection
[5]. We therefore assumed that the only persons treated
for latent TB infection would be individuals diagnosed
with concurrent HIV-latent TB infection (the latter
based on tuberculin test results) [20]. Of those treated,
we estimated only 67% would complete treatment for
latent infection [21].
HIV-related health states were divided into uninfected,
early HIV (asymptomatic), and late HIV (clinical AIDS).
The annual risk of HIV infection was estimated to be
Table 2 Model Pathogenetic Variables and Assumptions
Variable Value Source
HIV Infection
Annual risk of progression - asymptomatic to AIDS 7% [22,62]
Annual risk of death - early HIV (asymptomatic) 4.6% [22]
Annual risk of death - clinical AIDS 22% [22]
Median survival with early HIV 9.8 yrs [22,62]
Median survival with clinical AIDS 9 months [22]
Risk of developing active TB disease
HIV uninfected
Within 2 years of new TB infection 5% [17,63]
Within 2 years of re-infection after cured TB disease 1% [64,65]
Late re-activation from longstanding latent TB* 0.1%/year [18,19]
Early HIV
Within 2 years of new TB infection 33% Extrapolated
Within 2 years of re-infection after cured TB disease 33% Assumption
Late re-activation from longstanding latent TB* 3.4%/year [23,66,67]
Clinical AIDS
Within 2 years of new TB infection 100% [25,68-71]
Within 2 years of re-infection after cured TB disease 100% Assumption
Late re-activation from longstanding latent TB* 33%/year [23]
Untreated Smear Positive TB Outcomes (HIV-negative)
Spontaneous resolution 25% [72]
Relapse after spontaneous resolution 2.5%/year [72,73]
Mortality rate within 2 years 33% at 1 year; 50% at 2 years [74]
Untreated Smear Positive TB Outcomes (HIV-positive)
Spontaneous resolution 0% Assumption
Mortality rate within 2 years 100% Assumption
Treated Smear Positive TB Outcomes (HIV-negative)
Relapse after cure (total over next 2 years) 3.0% [75-79]
Cure rate if default (single drug resistant or drug sensitive)** 62.4% [80-83]
Effect of Drug Sensitivity on Treatment Outcomes
Relative risk of treatment failure - single drug resistant 2.0 [84]
Relative risk of treatment failure - multi-drug resistant 10.5 [84]
Relative risk of death - single drug resistant 1.0 [84]
Relative risk of death - multi-drug resistant 4.5 [84]
Multi-Drug Resistant TB Treatment Outcomes
Completed/Cured 68.6% [85]
Default/Failed/Transferred 17.1% [85]
Died 14.2% [85]
Treated Smear Positive TB Outcomes (HIV-positive)
Relative risk of death during TB treatment with HIV infection 2.25 [24,26,86,87]
Relapse after successful TB treatment (cured) 3.1% [88-90]
* Assumes rate of reactivation beyond 2 years after TB infection is the same whether it is after a first infection or after re-infection.
** Transfer out considered equivalent to default [91]. Overall cure rate if default based on timing of default [73], and cure rates from trials of very short course
treatment [81-83].
Tseng et al. BMC Public Health 2011, 11:55
http://www.biomedcentral.com/1471-2458/11/55
Page 4 of 160.96%, calculated from the adult population prevalence
of HIV in Zambia divided by the mean survival with
HIV infection in a low-income setting [10,22]. The risks
of TB progression, re-activation, relapse, and mortality
were assumed to be much higher in HIV-positive indivi-
duals [23-26]. These and other key pathogenetic
assumptions with respect to TB and HIV acquisition,
progression, and clinical outcomes are listed in Table 2.
Beginning from the first year, we estimated the pro-
portion of the cohort developing active TB, dying from
TB, dying from HIV, and dying from all other causes. In
each year, costs associated with each branch of the deci-
sion tree were determined and accumulated. Cohort
members surviving each year entered the subsequent
year of the simulation, starting in the health state deter-
mined by events of the preceding year. Final outcomes
including costs were multiplied by the size of the new-
born population to generate expected values over the
30-year simulation, for the cohort of newborns born in
Year 1. A simplified schematic of the decision tree is
shown in Figure 1.
Costs
Costs, expressed in 2007 U.S. dollars, were estimated
from a societal perspective. Direct costs included those
borne by the government and the healthcare system,
plus costs for implementation and maintenance. Indirect
costs included out-of-pocket expenditures by patients
and families, and lost productivity due to TB related dis-
ability and death. For children with TB, indirect costs
reflected costs borne by their families, namely family
members taking time off work and/or paying out-of-
pocket costs related to children’s illness and care. A
summary of direct and indirect costs per patient mana-
ged in Zambia is shown in Table 3.
Data regarding the number of health care visits and
out-of-pocket expenditures for patients and families in
the pre-diagnostic, hospitalization, treatment, and fol-
low-up phases were collected and analyzed from a pre-
vious survey of adult TB patients in Zambian urban
primary health care centres [27]. As we did not have
directly gathered data for costs to the Zambian health
care system, health care system costs were estimated
from a survey of Haitian TB care providers [15], where
the annual gross national income (GNI) per capita at
the time of the study in 2003 was similar to that of
Zambia now. Lost income due to TB-related medical
visits and TB-related premature death were determined
by the model based on GNI per capita, the number of
remaining years in the simulation, and the presence or
absence of HIV infection. The median length of survival
for HIV-infected persons was estimated to be 9.8 years
with early HIV and 9 months with clinical AIDS [22].
For adults with active TB. disability costs were calcu-
lated based on an assumed 50% reduction in productiv-
ity from symptom onset until diagnosis, and during the
first 2 months of treatment [28-30]. Untreated patients
or patients who failed treatment had a 50% reduction in
productivity for the duration of their illness.
Costs for the maintenance of the DOTS program were
based on detailed evaluations of DOTS implementation
in Ecuador [31], adjusted for gross national income per
capita in Zambia and converted to 2007 dollars using
the consumer price index [32]. Costs of anti-tuberculosis
drugs for active and latent TB were as listed by the Glo-
bal Drug Facility [33].
Initial research, development, and production costs for
single vaccination and prime-boost strategies were pro-
jected to be $141 million and $194 million respectively,
and prorated to the Zambian share (0.4%) of global
Figure 1 Sample decision analysis tree for Zambian newborn initially without HIV or TB infection.F o o t n o t e s :* States entered in
subsequent cycles not shown in this figure ** The letter “p” preceding a variable name denotes probability † Decision tree structure for HIV
infection not shown in this figure.
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collected prior to the 36
th IUATLD Conference in Paris
(2005) provided the basis for all vaccine costs [9], for
which the Aeras 403 recombinant BCG (rBCG) was
used as the replacement TB vaccine, and the Aeras 402
Crucell Ad35 vector expressing TB antigens was used as
the booster. Of note, we assumed no additional infra-
structure costs for distribution and delivery of a novel
vaccine, as an extensive program for BCG vaccination
already exists as part of the WHO Expanded Program
Table 3 Direct and indirect costs per tuberculosis patient managed in Zambia
Type of Cost Mean Source
Pre-Diagnosis
Number of medical visits 1.94 ZCQ
†
Lab costs (3 AFB smears) $8.49 [92]
Patient out-of-pocket expenditures for visits $10.63 ZCQ
†
Indirect Lost income for patient/family for visits* $1.47 ZCQ
†
Post-Diagnosis
Hospitalisation Number of hospital days 7.13 ZCQ
†
Direct Health system costs for hospital days $98.68 HCQ
‡
Patient out-of-pocket expenditures: hospital days $128.91 ZCQ
†
Indirect Lost income for patient/family for hospital days* $15.61 ZCQ
†
Direct Observation of Treatment (DOT)
Number of visits 108 ZCQ
†
Direct Health system costs for visits $78.84 HCQ
‡
Drug costs (new case) $5.37 [33]
Patient out-of-pocket expenditures for visits $15.12 ZCQ
†
Indirect Lost income for patient/family for visits* $51.84 ZCQ
†
Follow-up
Number of visits 7 ZCQ
†
Direct Health system costs for visits $27.44 HCQ
‡
Patient out-of-pocket expenditures for visits $0.84 ZCQ
†
Indirect Lost income for patient/family for visits* $4.06 ZCQ
†
Disability Costs
Direct Patient miscellaneous direct costs** $2.12 ZCQ
†
Indirect Lost income due to patient disability
¶ $138.10 ZCQ
†, HCQ
‡
Family miscellaneous indirect costs
¶¶ $46.44 HCQ
†
Total Cost per TB patient managed
Direct Health system $226.43
Patient out-of-pocket and miscellaneous costs $157.62
Indirect Patient/family lost income and miscellaneous costs $257.52
Total Health system and patient/family $641.57
Vaccination
Initial investment
§ - BCG replacement only $1.20/vaccinated [7,34,57]
With booster (total) $1.65/vaccinated [7,34,57]
Unit cost
§§ - BCG $2.00 [93]
BCG replacement only $1.10
†† [9]
With Booster (total) $3.40 [9]
† Values based on Zambian TB Cost Questionnaire 2006 [27].
‡ Values based on Haiti TB Patient Cost Questionnaire [15], where GNI per capita is similar to Zambia.
* Lost income based on average per capita gross national income - $500 - [58] and average work week of 40 hours.
** Direct patient/family expenditures (while ill with TB disease) that are in addition to money spent while visiting health establishments or hospitals
(e.g. cleaning, food supplements, childcare).
¶ Disability costs based on cure/complete treatment outcome (2 months disability) [28-30].
¶¶ Based on total hours spent by family members helping patient at home.
§ Initial investment includes research, development, and production costs.
§§ Unit cost includes distribution, administration, and vaccine dose costs.
†† BCG replacement unit cost estimates provided by Aeras [9] were lower than that of current BCG - likely secondary to improved manufacturing and/or
distribution efficiency.
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screening costs associated with vaccination would be the
same as for the current BCG program.
Sensitivity analyses
We performed extensive sensitivity analyses to test the
robustness of the model to a range of parameter values.
Key epidemiologic factors such as HIV prevalence and
TB infection risk were varied, where available, within
p u b l i s h e dr a n g e s .A s s u m e dc o s t sw e r ed o u b l e da n d
quadrupled to assess their impact on the cost effective-
ness of the vaccine strategies. To account for potentially
higher discount rates in low-income countries, we con-
sidered discount rates ranging from 2-6%. In addition,
combinations of unfavorable assumptions were used
to describe a “worst case” scenario. Since the first new
vaccines are now in the early and middle phases of
human clinical trials, there are no definitive efficacy
data. Therefore, we examined the effects of varying the
assumed efficacy and mechanism of action for the vac-
cine strategies. We considered prevention of acquisition
of initial infection, and prevention of late reactivation as
alternate mechanisms for vaccine action.
This study used a hypothetical simulation model based
on previously published data, so research ethics commit-
tee approval was not required. McGill University, the
Fonds de la Recherche en Santé du Québec, and the
Canadian Institutes of Health Research provided salary
support to the researchers, but had no role in any aspect
of this study. All members of the research team had full
access to all data and to the decision analysis model.
Results
With the status quo, the model projected 25,557 active
TB cases and 18,379 TB-related deaths over a period of
30 years, among 468,073 Zambians born in Year 1. The
associated direct costs were $11.4 million and indirect
costs were $45.1 million. Relative to current TB control
measures, a BCG replacement vaccine administered at
birth, with 70% efficacy in preventing rapid progression
to TB disease after initial infection, is estimated to pre-
vent 932 active TB cases and 422 TB-related deaths
over the same period. This corresponds to a reduction
of 199 cases and 90 deaths per 100,000 vaccinated. The
prevention of these active TB cases and TB-related
deaths would decrease direct costs by $0.2 million, and
indirect costs by $3.4 million, resulting in a net reduc-
tion of $3.6 million in societal costs. Hence a new vac-
cine is predicted to result in cost savings as well as
reduced morbidity and mortality.
The addition of a booster vaccine dose would avert
1,863 active TB cases and 1,011 TB-related deaths as com-
pared to the status quo–a further reduction of 931 TB
cases and 589 TB-related deaths beyond a single neonatal
dose of the new vaccine. However, this would increase
total direct costs to $11.9 million, reflecting larger invest-
ment in research, development, distribution, and vaccine
administration. Substantial indirect cost savings of $6.2
million however, would produce net societal cost savings
of $5.6 million compared to the status quo, or $2.0 million
compared to a single dose of the new vaccine at birth.
Tables 4 and 5 summarize TB related costs, TB mor-
bidity and mortality for each strategy over varying time
horizons, for the entire group of newborns (Table 4),
and per 100,000 newborns (Table 5). With vaccination
at birth alone, net savings for Zambia would begin
within 1 year, whereas the prime-boost strategy would
require an additional 5 years to realize savings - reflect-
ing greater initial development costs (Figure 2). In the
long run (>16 years), the prime-boost vaccination strat-
egy would be the cheapest.
Sensitivity analyses
Table 6 summarizes sensitivity analyses for key para-
meters. Net cost savings related to prevention of addi-
tional TB cases would be expected even if the initial
cost of research and development were quadrupled, or if
the vaccine unit cost were quadrupled. If the vaccine’s
duration of action were halved to 5 years, BCG replace-
ment vaccination at birth alone would produce a total
added societal cost of $0.55 million, and prevent fewer
TB cases than the current BCG vaccine, which had an
assumed duration of action of 10 years. However, with
the prime-boost vaccination strategy there were pre-
dicted societal cost savings even when the vaccine’s
duration of action was halved.
Savings as well as prevention of morbidity and mortal-
ity would increase for both vaccination strategies if the
prevalence of HIV were higher, reflecting the effect of
concurrent HIV infection on risks of rapid primary TB
progression and late TB re-activation. Similarly, if the
annual risk of TB infection were higher, cost savings
would increase. Conversely, with decreases in HIV pre-
valence or in the annual risk of TB infection, the num-
ber of TB cases prevented by vaccination would
decrease. Nonetheless, net cost savings are expected
with both vaccine strategies even with a 50% reduction
in HIV prevalence or a 50% reduction in the annual risk
of TB infection. With increases in the annual discount
rate, projected cost savings decrease as do TB cases pre-
vented and deaths prevented. Net cost savings are pre-
dicted for both vaccine strategies even when the
discount rate is doubled, to 6%.
In a “worst case” scenario where three key assump-
tions were made less favorable (initial development cost
doubled, vaccine unit cost doubled, vaccine duration of
action halved), both vaccination strategies would be
associated with increased societal costs as compared to
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dose, 98 more TB cases and 87 more TB deaths would
be expected, as well as higher societal costs. For the
prime-boost strategy, additional societal costs would
then be $77 per case prevented, and $160 per death
averted, as compared to the status quo.
Changing the predicted efficacy and assumed mechan-
ism of action showed that vaccines with efficacy ≥60%
and 50% targeting rapid progression and acquisition of
infection respectively, would be cost-saving relative to
current conditions (Figures 3 and 4). Due to the low
annual risk of re-activation in HIV-negative persons
(0.1%), the spreading of risk over a lifetime, and loss of
partial protection against rapid primary progression con-
ferred by the current BCG vaccine, a vaccine targeting
late reactivation alone would be more costly than the
status quo, even with 90% efficacy (Figure 5). Of course,
av a c c i n et h a ti ss a f ea n de f f e c t i v ei np r e v e n t i n gl a t e
reactivation is likely to be widely administered through-
out the community (not only to newborns), a scenario
that was beyond the scope of the present analysis.
Discussion
Our comparison of two vaccination strategies with the
current DOTS and BCG vaccination strategy for tuber-
culosis control in Zambia suggest that improved vac-
cines could reduce TB-related mortality and morbidity,
and produce cost savings over a 30-year time horizon.
The projections were generally robust in sensitivity ana-
lyses, even with assumed protective efficacy of 60% with
a novel vaccine. Not surprisingly, neonatal vaccines
which target initial infection or rapid progression will be
more cost-effective in the short-term than those which
target late re-activation. The current pipeline for novel
vaccines predominantly focuses on these mechanisms of
action [8,35].
Table 4 Cost and effectiveness of three strategies for tuberculosis control in Zambian newborns over 30 years, for the
total cohort of 468,073 newborns
Strategies Total Costs Direct Costs Indirect Costs TB Cases TB Mortality
Ranked from least to most expensive with respect to total cost $ million $ million $ million
After 5 years Novel TB vaccine at birth 7.123 3.348 3.775 5,771 2,861
Status quo 8.154 3.539 4.615 6,643 3,215
Novel TB vaccine at birth with Booster 8.347 4.572 3.775 5,771 2,861
After 10 years Novel TB vaccine at birth 16.702 5.721 10.981 11,608 6,452
Novel TB vaccine at birth with Booster 17.926 6.945 10.981 11,608 6,452
Status quo 18.754 5.980 12.774 12,592 6,896
After 20 years Novel TB vaccine at birth with Booster 36.486 10.129 26.357 19,388 12,772
Novel TB vaccine at birth 37.459 9.330 28.129 20,366 13,380
Status quo 40.463 9.583 30.880 21,305 13,808
After 30 years Novel TB vaccine at birth with Booster 50.876 11.930 38.946 23,694 17,368
Novel TB vaccine at birth 52.863 11.126 41.737 24,625 17,957
Status quo 56.481 11.377 45.104 25,557 18,379
Table 5 Cost and effectiveness of three strategies for tuberculosis control in Zambian newborns over 30 years, per
100,000 newborns
Strategies Total Costs Direct Costs Indirect Costs TB Cases TB Mortality
Ranked from least to most expensive with respect to total cost $million $million $million
After 5 years Novel TB vaccine at birth 1.522 0.715 0.806 1,233 611
Status quo 1.742 0.756 0.986 1,419 687
Novel TB vaccine at birth with Booster 1.783 0.977 0.806 1,233 611
After 10 years Novel TB vaccine at birth 3.568 1.222 2.346 2,480 1,378
Novel TB vaccine at birth with Booster 3.830 1.484 2.346 2,480 1,378
Status quo 4.007 1.278 2.729 2,690 1,473
After 20 years Novel TB vaccine at birth with Booster 7.795 2.164 5.631 4,142 2,729
Novel TB vaccine at birth 8.003 1.993 6.010 4,351 2,859
Status quo 8.645 2.047 6.597 4,552 2,950
After 30 years Novel TB vaccine at birth with Booster 10.869 2.549 8.320 5,062 3,711
Novel TB vaccine at birth 11.294 2.377 8.917 5,261 3,836
Status quo 12.067 2.431 9.636 5,460 3,927
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Page 8 of 16A previous analysis examined the public health impact
of new tuberculosis vaccines and predicted that a pre-
exposure vaccine, targeting the acquisition of infection
or primary progression would be effective at preventing
a substantial proportion of active TB cases. Although
such a vaccine would not benefit persons who have
already become infected with Mycobacterium tuberculo-
sis, it would nonetheless provide important public health
gains with respect to tuberculosis-related morbidity and
mortality. The authors predicted that a pre-exposure
vaccine that acts solely by reducing later reactivation of
latent infection would not have the same impact, even if
the vaccine were highly efficacious [36]. Our findings
are similar and concordant with another recent analysis
that used different modeling methods [37]. Over the
long term, any vaccine that reduces late reactivation will
decrease the annual risk of TB infection and therefore
decrease disease incidence. However, the low annual
risk of re-activation in HIV-negative persons, combined
with finite vaccine duration of action make such a vac-
cine less cost-effective in the short or medium term.
The cost-effectiveness of a vaccine targeting late reac-
tivation will be enhanced if it provides longer lasting
immunity, and potentially if it is administered only after
the acquisition of latent infection. One report estimated
that a pre-exposure vaccine with efficacy of 50% - 90%,
with a single mechanism of action, may only be capable
of reducing TB morbidity by one third over the long
term [36]. However, a more recent analysis concluded
that a neonatal vaccine could reduce TB incidence by
39-55% in the long term, while a mass pre-exposure
vaccine campaign could reduce incidence by 67%, in the
absence of HIV infection [38]. The same analysis sug-
gested that the combination of pre- and post- exposure
vaccines could reduce TB incidence by 79% in Southeast
Asia by 2050, in the absence of HIV infection. Hence, a
TB control strategy that combines the DOTS program
with vaccines targeting both early infection/progression
and late reactivation may ultimately be considered.
The duration of vaccine-induced immunity remains
unclear for the current BCG vaccine [6,39,40], so no
concrete estimates exist for novel BCG replacement vac-
cines. For a vaccine with waning efficacy, a prime-boost
strategy would be more cost-effective in the long term
(Figure 2); however, the time lag to net savings may pre-
sent a barrier to investment by both the public and pri-
vate sectors.
A limitation of our analysis was the prorated attribu-
tion of the initial vaccine development, research, and
production costs to Zambia, in proportion to its current
share of global BCG vaccination coverage (0.398%). At
this point in vaccine development there remains great
uncertainty about the ultimate cost of research, pre-clin-
ical and clinical trials, and vaccine rollout. It is quite
conceivable that these costs will exceed the estimates
used in our primary analysis. However, sensitivity ana-
lyses suggested cost savings for the neonatal replace-
ment vaccine, even if the initial investment and vaccine
Figure 2 Net savings or added cost of vaccine strategies over 30 years relative to status quo.
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Page 9 of 16unit costs were both quadrupled. Our prorating of
development costs to a single cohort of newborns is also
conservative, as it tends to underestimate the cost-effec-
tiveness of TB vaccines over time.
In fact, high-incidence low- and middle- income coun-
tries which will use novel TB vaccines may bear little of
their initial development costs. The funds may be pro-
vided primarily by governments of high-income coun-
tries, non-governmental organizations and research
grants. This means that from the perspective of high-
incidence countries and their populations, novel tuber-
culosis vaccines will be even more cost-effective. On the
other hand, from the broader global TB control perspec-
tive, which includes costs to funders, these costs are
relevant to the present analysis.
We did not model potential adverse events related to
the administration of tuberculosis vaccines in neonates.
An open-label, phase I trial of a novel vaccine candidate
has demonstrated safety and high immunogenicity in
individuals with latent tuberculosis infection [41]. The
frequency of disseminated BCG has been reported to be
less than five per million, and is mainly associated with
congenital immunocompromised states [42]. A recent
revision to the WHO guidelines on BCG vaccination
Table 6 Sensitivity analysis of vaccine strategies for tuberculosis control in Zambia, for the total cohort of 468,073
newborns
Parameter Varied No. of TB cases
prevented*
Change in Direct
Costs† $ million
Change in Indirect
Costs† $ million
Change in Total
Costs† $ million
All values are relative to the status quo strategy over 30 years
Novel TB Vaccine at Birth
Base case (no change in parameters) 932 ($0.25) ($3.37) ($3.62)
Initial investment doubled 932 $0.31 ($3.37) ($3.06)
Initial investment quadrupled 932 $1.44 ($3.37) ($1.93)
Vaccine unit costs doubled 932 $0.24 ($3.37) ($3.13)
Vaccine unit costs quadrupled 932 $1.20 ($3.37) ($2.17)
Initial investment & vaccine unit costs doubled 932 $0.79 ($3.37) ($2.58)
Initial investment & vaccine unit costs quadrupled 932 $2.89 ($3.37) ($0.48)
Vaccine duration of action halved (5 yrs) (98) $0.22 $0.33 $0.55
Initial investment & vaccine unit costs doubled &
vaccine duration of action halved
(98) $1.26 $0.33 $1.59
HIV prevalence increased by 50% 1,020 ($0.28) ($3.57) ($3.85)
HIV prevalence decreased by 50% 833 ($0.23) ($3.16) ($3.39)
Annual risk of TB infection increased by 50% 1,297 ($0.41) ($4.67) ($5.08)
Annual risk of TB infection decreased by 50% 501 ($0.06) ($1.83) ($1.89)
Discount rate 2% annually 936 ($0.26) ($3.79) ($4.05)
Discount rate 6% annually 899 ($0.23) ($2.46) ($2.69)
Novel TB Vaccine at Birth with Booster
Base case (no change in parameters) 1,863 $0.55 ($6.16) ($5.61)
Initial investment doubled 1,863 $1.33 ($6.16) ($4.83)
Initial investment quadrupled 1,863 $2.87 ($6.16) ($3.29)
Vaccine unit costs doubled 1,863 $2.05 ($6.16) ($4.11)
Vaccine unit costs quadrupled 1,863 $5.05 ($6.16) ($1.11)
Initial investment & vaccine unit costs doubled 1863 $2.82 ($6.16) ($3.34)
Initial investment & vaccine unit costs quadrupled 1,863 $7.36 ($6.16) $1.20
Vaccine duration of action halved (5 yrs) 904 $0.98 ($3.18) ($2.20)
Initial investment & vaccine unit costs doubled &
vaccine duration of action halved
904 $3.25 ($3.18) $0.07
HIV prevalence increased by 50% 1,994 $0.53 ($6.48) ($5.95)
HIV prevalence decreased by 50% 1,718 $0.58 ($5.81) ($5.23)
Annual risk of TB infection increased by 50% 2,294 $0.37 ($7.64) ($7.27)
Annual risk of TB infection decreased by 50% 1,151 $0.87 ($3.78) ($2.91)
Discount rate 2% annually 1,985 $0.59 ($7.15) ($6.56)
Discount rate 6% annually 1,568 $0.45 ($4.09) ($3.64)
*For TB cases prevented, values in parentheses indicate a net increase in TB cases.
†For costs: values in parentheses indicate net savings, values without parentheses indicate net cost increases.
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Page 10 of 16Figure 3 Effect of varying vaccine and booster efficacy when mechanism is prevention of rapid TB progression. Protective effect acting
on rapid TB progression only - none at initial infection or re-activation - on the projected total costs over 30-years.
Figure 4 Effect of varying vaccine and booster efficacy when mechanism is prevention of initial TB infection Protective effect acting on
initial TB infection only - none at rapid progression or re-activation - on the projected total costs over 30 years.
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Page 11 of 16recommends the immunization of asymptomatic infants
whose HIV status is unknown, but advises against
immunization of 1) infants whose HIV status is
unknown, but display signs or symptoms suggestive of
HIV infection; and 2) HIV positive infants, regardless of
signs or symptoms [43]. A previous study showed that
the risk of disseminated BCG disease is increased several
hundredfold in HIV-infected infants compared to the
documented risk in HIV-uninfected infants [44]. Unfor-
tunately, due to the transplacental passage of maternal
HIV antibodies, accurate diagnosis in the neonatal per-
iod requires the demonstration of HIV DNA, or HIV
RNA and p24 antigen. Furthermore, signs of HIV infec-
tion are uncommon prior to BCG vaccine administra-
tion in the first weeks of life. For these reasons, the
current program for BCG vaccination may have reduced
efficacy in a particularly high-risk group, and increased
morbidity, mortality, and added costs may result from
BCG-related adverse events in countries with high HIV
prevalence such as Zambia. Conversely, safety in HIV-
infected neonates is considered a prerequisite for any
future neonatal TB vaccine.
Other potential limitations of the analysis included
our assumptions of stability in population size and age
distribution, and HIV parameters. Herd immunity was
not modeled [45], but a reduction in the annual risk of
TB infection resulting from any vaccine which prevents
contagious pulmonary TB would further reduce TB
morbidity and mortality. Similarly, we did not model
transmission, since the primary analysis considered vac-
cine protection among children, in whom TB is rarely
contagious. Again, this makes our model conservative in
that it tends to underestimate potential vaccine benefits.
A challenge to TB vaccine development is the lack of
proven immunological correlates of vaccine-induced
immunity, although early animal studies suggest
improved protection against a pulmonary TB challenge
for several prime-boost approaches [46-48]. We did not
model the effects of M. tuberculosis strain diversity. A
recent analysis suggests the efficacy of novel vaccines
may differ against different strains of the bacteria [49],
however, the precise impact on efficacy remains uncer-
tain given our incomplete knowledge regarding how
distinct strains interact and the strain specificity of
current vaccine candidates.
Our findings remained consistent across different sce-
narios for HIV seroprevalence. Greater savings and
reduction in TB-related morbidity and mortality would
be achieved if HIV seroprevalence was higher, owing to
the more frequent development of active TB following
Figure 5 Effect of varying vaccine and booster efficacy when mechanism is prevention of late TB re-activation. Protective effect acting
on late TB re-activation only - none at initial infection or rapid progression - on the projected total costs over 30 years.
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Page 12 of 16infection. An increase in the proportion of TB which is
multi-drug resistant would yield greater cost savings for
vaccination, because of increased treatment and patient/
family costs for MDR-TB. We computed the annual risk
of TB infection from the incidence of smear-positive
cases using the Styblo formula, which has been criticized
[50]. Furthermore, a recent study has shown that in the
presence of a strong control program, the TB incidence
is not necessarily reflective of the true annual risk of TB
infection in a country with high HIV seroprevalence
[51]. However, we substantially varied the assumed
annual risk of TB infection, and demonstrated that both
primary vaccination strategies considered would still
result in cost savings. Any inaccuracy in estimating the
annual risk of TB infection would apply equally to all
strategies, and would not tend to favor one particular
strategy over the others.
Health care system costs were approximated by pre-
viously published data in Haiti, where GNI per capita is
similar to Zambia. Social, political, and economic differ-
ences between the two countries may affect the validity
of these estimates. However, indirect costs, which were
obtained from Zambia itself, accounted for the bulk of
total societal costs, strengthening our cost estimates. As
a case study, our results may not be directly applicable
to other sub-Saharan African countries given variability
in epidemiology and economics, but the flexibility of the
decision analysis model suggests the potential for a simi-
lar approach.
Several strengths of the analysis deserve comment. We
considered the effect of HIV infection on TB pathogen-
esis, and accounted for survival with asymptomatic HIV
and clinical AIDS, since HIV prevalence is high in Zam-
bia and other sub-Saharan African countries [10]. Pub-
lished values were used for epidemiologic data, TB
pathogenesis, HIV pathogenesis, and treatment out-
comes whenever available, thereby reducing uncertainty.
We evaluated costs from a societal perspective, and con-
sidered both direct and indirect costs from the stand-
point of a low-income country with high TB incidence.
Notably, indirect costs borne by patients and families
constituted a substantial proportion of the total. The
decision analysis model allowed us to manipulate key
variables and test our underlying assumptions. Sensitiv-
ity analyses confirmed the robustness of the main find-
ings. In particular, with an assumed efficacy of 60%, a
novel vaccine that prevents rapid progression to active
TB would still provide cost savings, as well as prevent
TB cases and TB-related deaths. This strengthens the
economic argument in favour of developing and imple-
menting new vaccines. We recognize that the 70%
efficacy estimate used for our primary analysis is specu-
lative, as useful evidence must await the outcome of one
or more large-scale clinical trials, still years away.
Novel TB vaccine development and deployment faces
a number of obstacles. The lack of validated biomar-
kers for candidate vaccine selection, scarcity of suitable
field sites, exclusion of at-risk populations from trials,
regulatory issues, and complex ethical concerns at each
stage of human testing are among the challenges
[52-54]. The continued expansion of the TB vaccine
pipeline, however, remains reassuring. Recent years
have renewed interest in TB vaccine development. By
the end of 2009, at least nine novel TB vaccines were
undergoing evaluation in humans, with at least two
recombinant protein vaccines reaching phase II trials
[54,55].
Conclusions
This analysis suggests that a prime-boost strategy using
a tuberculosis vaccine with moderate efficacy (>60%)
which prevents initial infection or rapid primary
progression to disease, will be the most cost-effective
vaccine intervention over the short to medium term, in
high-burden countries. We conclude that investment in
an improved TB vaccine may result in considerable cost
savings, as well as a reduction in TB morbidity and
TB-related mortality, when it enhances existing control
strategies.
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